GLP-1 Science
What Is a GLP-1 Receptor Agonist? A Simple Explanation
GLP-1 receptor agonists are drugs that mimic the fullness hormone GLP-1. Ozempic, Wegovy, and Mounjaro are all in this c...
Oral and injectable semaglutide are the same drug delivered differently. Both contain semaglutide — the GLP-1 receptor agonist in Ozempic and Wegovy. The difference is how well each gets into your bloodstream, which determines how much of the drug actually reaches GLP-1 receptors and produces effect.
Injectable semaglutide bypasses the digestive system entirely. Oral semaglutide must survive the gut environment to reach the bloodstream — and very little of it does.
Injectable Semaglutide (Ozempic, Wegovy)
Injectable semaglutide is administered once weekly as a subcutaneous injection — delivered under the skin of the abdomen, thigh, or upper arm. It enters the bloodstream directly through subcutaneous absorption, with bioavailability approaching 100%.
Once weekly injectable dosing produces stable semaglutide blood levels maintained throughout the week. This consistency drives the steady, sustained appetite suppression and metabolic effects documented in the STEP clinical trials.
The maximum dose of Ozempic is 2 mg weekly. Wegovy reaches 2.4 mg. These doses produce the 9 to 15% average weight loss documented in clinical trials.
Oral Semaglutide (Rybelsus)
Rybelsus is an oral semaglutide tablet available in 3 mg, 7 mg, and 14 mg doses. It is approved only for type 2 diabetes, not for obesity management.
The bioavailability problem is significant: oral semaglutide achieves only about 1% absorption through the gut wall. This is why the 14 mg oral dose is needed to achieve blood levels comparable to the 1 mg injection. The drug includes a co-formulated absorption enhancer (SNAC — sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to partially overcome this limitation.
Even with this enhancer, oral bioavailability is highly variable and sensitive to food, water, and stomach acidity. Rybelsus must be taken on an empty stomach with a maximum of 120 ml of water, and the patient must wait at least 30 minutes before eating or drinking anything else. Missing these conditions substantially reduces absorption.
The weight loss effect of Rybelsus at 14 mg is meaningful but less than Ozempic at 1 mg — reflecting the lower circulating semaglutide levels even at higher tablet doses.
A Third Option: Sublingual Delivery
Between injections and gut absorption sits a more efficient oral route: sublingual delivery — holding the drug under the tongue where it absorbs directly into the bloodstream through the mucous membrane, bypassing the gut wall entirely.
METASLIM delivers GLP-1 support through sublingual drops at 2000 mcg/ml — held under the tongue for 60 seconds, absorbing into the bloodstream without either a needle or the gut absorption limitation that makes oral semaglutide require such high doses. For Pakistani patients, it is the only DRAP-registered GLP-1 sublingual option currently available — combining the needle-free convenience of oral delivery with absorption more comparable to injection than tablet.
How They Compare Practically
| | Injectable (Ozempic) | Oral (Rybelsus) | Sublingual (METASLIM) | |---|---|---|---| | Frequency | Once weekly | Once daily | Daily | | Bioavailability | ~100% | ~1% | High (direct mucous membrane) | | Needle | Yes | No | No | | Food restriction | No | Yes (empty stomach) | No | | DRAP registered (Pakistan) | No | No | Yes |